Paradigm Biopharmaceuticals Ltd.ASX: PAR

Ema provides key path toward phase 3 trials and registration

Sep 28, 2020 at 3:14 AM UTC · Issued by Paradigm Biopharmaceuticals Ltd.

Paradigm Biopharmaceuticals Ltd has released a press release.

View Attachment